Technology to overcome clinical inertia in insulin therapy

Lancet. 2019 Mar 16;393(10176):1078-1080. doi: 10.1016/S0140-6736(19)30416-7. Epub 2019 Feb 23.

Authors

Mark L Evans¹, Rajna Golubic²

Affiliations

¹ Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK. Electronic address: [email protected].
² Wellcome Trust, MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge NIHR Biomedical Campus, Cambridge CB20QQ, UK.

PMID: 30808513
DOI: 10.1016/S0140-6736(19)30416-7

No abstract available

MeSH terms

Algorithms
Biomedical Technology / methods
Blood Glucose / drug effects*
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Drug Delivery Systems / instrumentation*
Female
Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors
Glucagon-Like Peptide-1 Receptor / therapeutic use
Glycated Hemoglobin / analysis
Glycated Hemoglobin / metabolism*
Humans
Insulin / administration & dosage
Insulin / adverse effects
Insulin / therapeutic use*
Male
Physicians, Primary Care
Treatment Outcome

Substances

Blood Glucose
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A
Insulin